EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mucormycosis

Dimitrios P Kontoyiannis, Thomas J Walsh

New England Journal of Medicine · 12.02.2026 · 394 (7) · 684-698

DOI: 10.1056/nejmra2412565 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, erschienen am 12.02.2026. Verfasst von Dimitrios P Kontoyiannis und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M.D. Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Antifungal Agents, Immunocompromised Host, Mucorales, Mucormycosis. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 93 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucormycosis is a rapidly progressive, invasive fungal infection that affects patients who are severely immunocompromised, as well as patients with diabetes and persons with immunocompetence who have major trauma. Mucormycosis manifests in several clinical forms, including sino-orbital, rhinocerebral, sinopulmonary, gastrointestinal, cutaneous, musculoskeletal, osteoarticular, and disseminated mucormycosis, as well as single-organ disease. Although mucormycosis is often lethal, early intervention reduces mortality. Successful treatment depends on early detection and staging of the disease, timely initiation of antifungal therapy, surgical resection of infected tissue, reversal of immunodeficiencies, and correction of metabolic abnormalities. Liposomal amphotericin B is the preferred agent for initial antifungal therapy, with oral triazoles as alternative agents. Research on rapid molecular diagnostic strategies, new antifungal agents, host-directed immune augmentation, antivirulence immune therapeutics, and risk-based stratification to inform management of disease may substantially improve outcomes in patients with this highly destructive mycosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsImmunocompromised HostMucoralesMucormycosisHost-Directed TherapyHumansAmphotericin BTriazoles

Substanzen

Amphotericin BAntifungal Agentsliposomal amphotericin BTriazoles

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas M.D. Anderson Cancer Center, Houston.
  • Center for Innovative Therapeutics and Diagnostics, Richmond, VA.
  • Department of Medicine, University of Maryland School of Medicine, Baltimore.
  • Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore.

Zitieren

APA

Kontoyiannis, D. P., & Walsh, T. J. (2026). Mucormycosis. New England Journal of Medicine, 394(7), 684-698. https://doi.org/10.1056/nejmra2412565

Vancouver

Kontoyiannis DP, Walsh TJ. Mucormycosis. New England Journal of Medicine. 2026;394(7):684-698. doi:10.1056/nejmra2412565

BibTeX
@article{Kontoyiannis2026,
  author = {Kontoyiannis, Dimitrios P and Walsh, Thomas J},
  title = {Mucormycosis},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {7},
  pages = {684--698},
  doi = {10.1056/nejmra2412565}
}
Kostenlos starten →